BB Biotech AG
ISIN-No.: CH0038389992
YTD: -12.06%
Active share: 81.54
Anzahl Positionen: 31
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Indexed performance (as at: 20.11.2024)
Share price: CHF 36.00 (19.11.2024)
NAV: CHF 42.25 (19.11.2024)
Rolling performance (20.11.2024)
| Share Price | NAV | Benchmark | |
| 19.11.2023 - 19.11.2024 | -2.99% | 13.30% | 16.36% |
| 19.11.2022 - 19.11.2023 | -28.65% | -21.10% | -15.83% |
| 19.11.2021 - 19.11.2022 | -22.52% | -8.39% | -8.21% |
| 19.11.2020 - 19.11.2021 | 23.22% | 4.46% | 14.12% |
Annualized performance (20.11.2024)
| Share Price | NAV | Benchmark | |
| 1 year | -2.99% | 13.30% | 16.36% |
| 3 years | -18.76% | -6.44% | -3.67% |
| 5 years | -6.73% | -0.52% | 3.12% |
| 10 years | 3.12% | 2.74% | 3.36% |
| Since Inception p.a. | 9.64% | 10.21% | 8.83% |
Cumulative performance (20.11.2024)
| Share Price | NAV | Benchmark | |
| 1M | -3.61% | -4.52% | -7.07% |
| YTD | -12.06% | 4.21% | 6.54% |
| 1 year | -2.99% | 13.30% | 16.36% |
| 3 years | -46.37% | -18.11% | -10.61% |
| 5 years | -29.43% | -2.56% | 16.62% |
| 10 years | 35.94% | 31.09% | 39.18% |
| Since Inception | 1'640.92% | 1'942.02% | 1'283.16% |
Annual performance
| Share Price | NAV | Benchmark | |
| 2023 | -18.15% | -7.39% | -4.79% |
| 2022 | -24.29% | -11.00% | -9.09% |
| 2021 | 8.34% | -11.45% | 2.98% |
| 2020 | 19.35% | 24.26% | 15.80% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BION SW Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | Incorporate company |
| SFDR category | Article 8 |
Key data (31.10.2024, base currency CHF)
| Beta | 1.34 |
| Volatility | 32.20 |
| Tracking error | 14.98 |
| Active share | 81.54 |
| Correlation | 0.92 |
| Sharpe ratio | -0.09 |
| Information ratio | -0.01 |
| Jensen's alpha | 0.83 |
| No. of positions | 31 |
Portfolio as at 30.09.2024
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
BB Biotech reported its third quarter result on October 25. The full report can be read on www.bbbiotech.com. In the third quarter, portfolio adjustments focused on capitalizing on gains from larger, long-term holdings in line with BB Biotech’s S-curve investment strategy. This allowed us to reallocate capital into selectively identified companies with strong growth trajectories, further advancing our continuous portfolio rejuvenation. By rotating investments strategically, we aim to enhance exposure to promising novel assets while staying aligned with our long-term objectives.
Please find below selected highlights from a few of BB Biotech´s portfolio companies in October:
Scholar Rock (+255.1%, in USD) announced on October 7 positive topline results from the Phase III SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab, an investigational muscle-targeted therapy, in patients with SMA. The study achieved its primary endpoint demonstrating a statistically significant and clinically meaningful improvement for apitegromab versus placebo.
Wave Life Sciences (+67.2%, in USD) announced on October 16 positive proof-of-mechanism data from the ongoing Phase Ib/IIa RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD). WVE-006 was developed with Wave’s best-in-class oligonucleotide chemistry platform. It is uniquely designed to address AATD-related lung disease, liver disease, or both.
Revolution Medicines (+18.0%, in USD) announced on October 25 preliminary safety and antitumor data for RMC-9805 in patients with previously treated pancreatic ductal adenocarcinoma (PDAC). These initial results were presented during the late-breaking oral session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 25, 2024.
Essa Pharma (-14.2%, in USD (share price reacted strongly negatively on November 1)) announced on October 31 that it has made the decision to terminate a Phase II clinical trial. This decision, mutually agreed upon by both senior management and the board of directors, was based on a protocol-specified interim review of the safety, PK and efficacy data, which showed a much higher rate of PSA90 response in patients treated with enzalutamide monotherapy (which is standard of care for this patient population) than were expected based upon historical data. In addition, there was no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent.
Documents
Show moreShow less
